

Andrew L. Folpe, MD

Mayo Clinic, Rochester MN

Arthur Purdy Stout Society of Pathology Companion Meeting, USCAP 2017

Selected References

1. Denk H, Krepler R, Artlieb U, Gabbiani G, Rungger-Brandle E, Leoncini P, et al. Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. *Am J Pathol.* 1983;110(2):193-208.
2. Gown AM, Vogel AM, Gordon D, Lu PL. A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes. *Journal of Cell Biology.* 1985;100(3):807-13.
3. Gray MH, Rosenberg AE, Dickersin GR, Bhan AK. Cytokeratin expression in epithelioid vascular neoplasms. *Hum Pathol.* 1990;21(2):212-7.
4. Miettinen M, Franssila K. Immunohistochemical spectrum of malignant melanoma. The common presence of keratins. *Lab Invest.* 1989;61(6):623-8.
5. Romano RC, Carter JM, Folpe AL. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases. *Mod Pathol.* 2015;28(8):1033-42.
6. Tessier Cloutier B, Costa FD, Tazelaar HD, Folpe AL. Aberrant expression of neuroendocrine markers in angiosarcoma: a potential diagnostic pitfall. *Human Pathology.* 2014;45(8):1618-24.
7. McKenney JK, Weiss SW, Folpe AL. CD31 expression in intratumoral macrophages: a potential diagnostic pitfall. *Am J Surg Pathol.* 2001;25(9):1167-73.
8. Gu M, Antonescu CR, Guiter G, Huvos AG, Ladanyi M, Zakowski MF. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. *Am J Surg Pathol.* 2000;24(3):410-6.
9. Folpe AL, Goldblum JR, Rubin BP, Shehata BM, Liu W, Dei Tos AP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. *Am J Surg Pathol.* 2005;29(8):1025-33.
10. Fanburg-Smith JC, Majidi M, Miettinen M. Keratin expression in schwannoma; a study of 115 retroperitoneal and 22 peripheral schwannomas. *Mod Pathol.* 2006;19(1):115-21.
11. Eyden B, Pandit D, Banerjee SS. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases. *Histopathology.* 2005;47(4):402-9.
12. Folpe AL, Weiss SW, Fletcher CDM, Gown AM. Tenosynovial giant cell tumors: Evidence for a desmin-positive dendritic cell subpopulation. *Modern Pathology.* 1998;11(10):939-44.
13. Graham RP, Dry S, Li X, Binder S, Bahrami A, Raimondi SC, et al. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic, proteomic, and genomic study. *Am J Surg Pathol.* 2011;35(11):1615-25.
14. Antonescu CR, Sung YS, Chen CL, Zhang L, Chen HW, Singer S, et al. Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. *Genes Chromosomes Cancer.* 2014;53(2):183-93.

15. Somerhausen NS, Fletcher CD. Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. *American Journal of Surgical Pathology*. 2000;24(4):479-92.
16. Thway K. Angiomatoid fibrous histiocytoma: a review with recent genetic findings. *Archives of Pathology & Laboratory Medicine*. 2008;132(2):273-7.
17. Harris M, Coyne J, Tariq M, Eyden BP, Atkinson M, Freemont AJ, et al. Extraskeletal myxoid chondrosarcoma with neuroendocrine differentiation: a pathologic, cytogenetic, and molecular study of a case with a novel translocation t(9;17)(q22;q11.2). *American Journal of Surgical Pathology*. 2000;24(7):1020-6.
18. Bahrami A, Gown AM, Baird GS, Hicks MJ, Folpe AL. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. *Mod Pathol*. 2008;21(7):795-806.